[{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"The Autism Impact Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yamo Pharmaceuticals \/ The Autism Impact Fund","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharmaceuticals \/ The Autism Impact Fund"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yamo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Racemetirosine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Yamo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Yamo Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Yamo Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : L1-79 is a tyrosine hydroxylase inhibitor expected to modulate the catecholaminergic pathways, and thereby improve the core autism spectrum disorder symptoms.

                          Brand Name : L1-79

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 30, 2024

                          Lead Product(s) : Methyltyrosine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : L1-79 (DL-alpha-Methyltyrosine) is a tyrosine hydroxylase inhibitor which is under phase 2 clinical development . It is designed to improve the core socialization and communication symptoms of autism spectrum disorder (ASD).

                          Brand Name : L1-79

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 20, 2023

                          Lead Product(s) : Methyltyrosine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : As part of investment in Yamo to support a Phase 2 study of L1-79 in adolescents and adults with ASD. L1-79, the company’s lead candidate, is a tyrosine hydroxylase inhibitor designed to modulate the catecholaminergic pathways implicated in ASD.

                          Brand Name : L1-79

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 10, 2021

                          Lead Product(s) : Methyltyrosine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : The Autism Impact Fund

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank